<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6015">
  <stage>Registered</stage>
  <submitdate>13/07/2016</submitdate>
  <approvaldate>13/07/2016</approvaldate>
  <nctid>NCT02859701</nctid>
  <trial_identification>
    <studytitle>Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants</studytitle>
    <scientifictitle>A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending and Multi Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AK002-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AK002
Other interventions - Placebo

Experimental: AK002 - AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses

Placebo Comparator: Placebo - Placebo administered as anl IV infusion


Treatment: drugs: AK002
IV AK002

Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety and tolerability of AK002 as assessed by incidence, nature and severity of AEs and SAEs.</outcome>
      <timepoint>Screening to day 112</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate pharmacokinetic parameter AUC for AK002.</outcome>
      <timepoint>Baseline to Day 112</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of absolute peripheral blood counts of eosinophils.</outcome>
      <timepoint>baseline to Day 112</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline of absolute peripheral blood counts of basophils.</outcome>
      <timepoint>baseline to Day 112</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in serum tryptase levels</outcome>
      <timepoint>baseline to Day 112</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate pharmacokinetic parameter CMAX for AK002.</outcome>
      <timepoint>baseline to day 112</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Eosinophilic Cationic protein levels</outcome>
      <timepoint>Baseline to day 112</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Normal healthy volunteers, age at screening 18 to 65 years, inclusive.

          2. Determined by the Investigator to be in good health, as documented by medical history,
             physical examination (including, but not limited to, an evaluation of the
             cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign
             assessments, clinical laboratory assessments, and by general observations.

          3. Participants must weigh at least 50 kg and have a Body Mass Index (BMI) between 18 and
             30 kg/m2 Inclusive.

          4. Participants must have clinical laboratory values within &lt;1.5 x upper limit of normal
             (ULN) as specified by the testing laboratory, unless deemed not clinically significant
             by the Investigator.

          5. Consumed an average of no more than 3 drinks per day within the 6 months prior to
             administration of study drug (beer [284 mL], wine [125 mL] or distilled spirits [25
             mL]).

          6. Participants must have a negative urine drug screen /alcohol breath test at screening
             and Day -1.

          7. Stool sample negative for parasites.

          8. Participants must have the ability and willingness to attend the necessary visits to
             the study centre.

          9. Written informed consent signed prior to entry into the study.

         10. Participants must be able to communicate effectively with the study site personnel.

         11. Participants using highly effective, double barrier contraception (both male and
             female partners) during the study and for 90 days following the dose of AK002</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HBsAg), or hepatitis C antibodies (HCV).

          2. The participant has any underlying physical or psychological medical condition that,
             in the opinion of the Investigator, would make it unlikely that the participant will
             complete the study.

          3. The participant has evidence of any medical or surgical disease or condition which, in
             the opinion of the Investigator, might compromise the haematologic, cardiovascular,
             pulmonary, renal, gastrointestinal, hepatic, skeletal, or central nervous system; or
             other conditions that may interfere with the absorption, distribution, metabolism or
             excretion of AK002, or would place the participant at increased risk.

          4. The participant has a history of cancer, except basal cell carcinoma which has been in
             remission for at least 5 years prior to Day 1

          5. Use of any new drugs (including prescription and over-the-counter drugs and herbal
             supplements) within 1 week or 5 half-lives (whichever is longer), prior to
             administration of study drug.

          6. Use of any prescription medication or neutraceuticals within 30 days of randomization.

          7. Use of over-the counter medication (with the exception of paracetamol), vitamin
             supplements, or herbal medicines within 7 days of randomization.

          8. Participants who initiated immunotherapy 90 days or more before the Screening visit
             and have been on a monthly regimen for allergy prevention or treatment may be
             considered for inclusion,

          9. Use of immunosuppressants, oral corticosteroids, angiotensin converting enzyme (ACE)
             inhibitors or beta blockers within 2 weeks or 5 half-lives (whichever is longer),
             prior to Screening.

         10. Any clinically significant laboratory abnormality or ECG.

         11. The participant has a known hypersensitivity to any component of the formulation of
             AK002.

         12. Absolute neutrophil count &lt;1500/microliter.

         13. Aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt;1.5 x ULN unless
             deemed not clinically significant by Investigator discretion.

         14. The participant has history or presence of alcoholism or drug abuse within the 2 years
             prior to the first study drug administration, or is unwilling to agree to abstain from
             alcohol limitations and drugs throughout the study.

         15. The participant has used nicotine-containing products (including but not limited to
             cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 3
             months prior to Check-in (Day -1). Cotinine urine test is positive at Screening or
             Check-in (Day -1).

         16. The participant has poor peripheral venous access.

         17. Blood donation or significant blood loss (more than 500 mL) within 60 days

         18. Plasma donation within 7 days prior to Day 1.

         19. Administration of Investigational Product (IP) in another trial within 30 days prior
             to the first study drug administration (or within 5 half lives of the drug, whichever
             is longer).

         20. Females who are pregnant or lactating or intend to become pregnant before, during, or
             within 90 days after participating in this study; or intending to donate ova during
             such time period.

         21. Surgery within the past three months prior to the first study drug administration
             determined by the PI to be clinically relevant.

         22. Failure to satisfy the PI of fitness to participate for any other reason.

         23. History of severe allergic or anaphylactic reactions.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>51</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>17/05/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Nucleus Network Limited - Melbourne</hospital>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Allakos, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Single-centre, randomised, double blind, placebo controlled, single ascending dose study and
      multiple dose study. AK002 will be administered as an intra-venous (IV) infusion in eight
      cohorts of single escalating doses and two cohorts with multiple doses. The study will
      comprise of 3 parts: Part A (Cohorts 1 - single ascending dose); Part B (Cohorts 2 to 9 -
      single ascending dose); Part C (Cohorts 10 and 11 - multiple dose).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02859701</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason Lickliter, MBBS PhD</name>
      <address>Nucleus Network Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>